A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

NCT01668017 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor decided not to conduct the expansion part of trial (part 2)

Conditions

Advanced Solid Tumors
Hepatocellular Carcinoma

Interventions

DRUG: Pimasertib
DRUG: Pimasertib
DRUG: Pimasertib
DRUG: Pimasertib
DRUG: Pimasertib

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]